178 related articles for article (PubMed ID: 21735096)
21. Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells.
Rodríguez-Ulloa A; Ramos Y; Gil J; Perera Y; Castellanos-Serra L; García Y; Betancourt L; Besada V; González LJ; Fernández-de-Cossio J; Sanchez A; Serrano JM; Farina H; Alonso DF; Acevedo BE; Padrón G; Musacchio A; Perea SE
J Proteome Res; 2010 Oct; 9(10):5473-83. PubMed ID: 20804217
[TBL] [Abstract][Full Text] [Related]
22. Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection.
Ramón AC; Pérez GV; Caballero E; Rosales M; Aguilar D; Vázquez-Blomquist D; Ramos Y; Rodríguez-Ulloa A; Falcón V; Rodríguez-Moltó MP; Yang K; Perera Y; Perea SE
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336959
[TBL] [Abstract][Full Text] [Related]
23. Role of protein kinase CK2 phosphorylation in the molecular chaperone activity of nucleolar protein b23.
Szebeni A; Hingorani K; Negi S; Olson MO
J Biol Chem; 2003 Mar; 278(11):9107-15. PubMed ID: 12511551
[TBL] [Abstract][Full Text] [Related]
24. B23 is a downstream target of polyamine-modulated CK2.
Lawson K; Larentowicz L; Laury-Kleintop L; Gilmour SK
Mol Cell Biochem; 2005 Jun; 274(1-2):103-14. PubMed ID: 16342411
[TBL] [Abstract][Full Text] [Related]
25. Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells.
Rabalski AJ; Gyenis L; Litchfield DW
Clin Cancer Res; 2016 Jun; 22(12):2840-7. PubMed ID: 27306791
[TBL] [Abstract][Full Text] [Related]
26. Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects.
Zanin S; Sandre M; Cozza G; Ottaviani D; Marin O; Pinna LA; Ruzzene M
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1694-707. PubMed ID: 25936516
[TBL] [Abstract][Full Text] [Related]
27. CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo.
Farina HG; Benavent Acero F; Perera Y; Rodríguez A; Perea SE; Castro BA; Gomez R; Alonso DF; Gomez DE
Exp Cell Res; 2011 Jul; 317(12):1677-88. PubMed ID: 21565189
[TBL] [Abstract][Full Text] [Related]
28. CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition.
Rosales M; Rodríguez-Ulloa A; Pérez GV; Besada V; Soto T; Ramos Y; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
Front Mol Biosci; 2022; 9():834814. PubMed ID: 35359604
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines.
Vázquez-Blomquist D; Ramón AC; Rosales M; Pérez GV; Rosales A; Palenzuela D; Perera Y; Perea SE
BMC Genomics; 2023 Jul; 24(1):373. PubMed ID: 37400761
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).
Perea SE; Reyes O; Puchades Y; Mendoza O; Vispo NS; Torrens I; Santos A; Silva R; Acevedo B; López E; Falcón V; Alonso DF
Cancer Res; 2004 Oct; 64(19):7127-9. PubMed ID: 15466209
[TBL] [Abstract][Full Text] [Related]
31. Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.
Perera Y; Farina HG; Hernández I; Mendoza O; Serrano JM; Reyes O; Gómez DE; Gómez RE; Acevedo BE; Alonso DF; Perea SE
Int J Cancer; 2008 Jan; 122(1):57-62. PubMed ID: 17847034
[TBL] [Abstract][Full Text] [Related]
32. CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model.
Pérez GV; Rosales M; Ramón AC; Rodríguez-Ulloa A; Besada V; González LJ; Aguilar D; Vázquez-Blomquist D; Falcón V; Caballero E; Carvalho PC; Caldeira RS; Yang K; Perera Y; Perea SE
Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672551
[TBL] [Abstract][Full Text] [Related]
33. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.
Benavent Acero FR; Perera Negrin Y; Alonso DF; Perea SE; Gomez DE; Farina HG
Mol Pharm; 2014 Jun; 11(6):1798-807. PubMed ID: 24773585
[TBL] [Abstract][Full Text] [Related]
35. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Choi S; Baldini C; Konstantinidou G; Pandolfi PP
Mol Cell Biochem; 2008 Sep; 316(1-2):149-54. PubMed ID: 18566754
[TBL] [Abstract][Full Text] [Related]
36. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
37. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
38. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
39. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.
Cruz LR; Baladrón I; Rittoles A; Díaz PA; Valenzuela C; Santana R; Vázquez MM; García A; Chacón D; Thompson D; Perera G; González A; Reyes R; Torres L; Pérez J; Valido Y; Rodriguez R; Vázquez-Bloomquist DM; Rosales M; Ramón AC; Pérez GV; Guillén G; Muzio V; Perera Y; Perea SE;
ACS Pharmacol Transl Sci; 2021 Feb; 4(1):206-212. PubMed ID: 33615173
[TBL] [Abstract][Full Text] [Related]
40. Development of a high-throughput screening-compatible assay to identify inhibitors of the CK2α/CK2β interaction.
Hochscherf J; Lindenblatt D; Steinkrüger M; Yoo E; Ulucan Ö; Herzig S; Issinger OG; Helms V; Götz C; Neundorf I; Niefind K; Pietsch M
Anal Biochem; 2015 Jan; 468():4-14. PubMed ID: 25233003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
